Skip to main content
Journal cover image

Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).

Publication ,  Journal Article
Kimmick, GG; Major, B; Clapp, J; Sloan, J; Pitcher, B; Ballman, K; Barginear, M; Freedman, RA; Artz, A; Klepin, HD; Lafky, JM; Hopkins, J ...
Published in: Breast Cancer Res Treat
June 2017

PURPOSE: Tools to estimate survival, such as ePrognosis ( http://eprognosis.ucsf.edu/carey2.php ), were developed for general, not cancer, populations. In older patients with breast cancer, accurate overall survival estimates would facilitate discussions about adjuvant therapies. METHODS: Secondary analyses were performed of data from two parallel breast cancer studies (CALGB/Alliance 49907/NCT000224102 and CALGB/Alliance 369901/NCT00068328). We included patients (n = 971) who were age 70 years and older with complete baseline quality of life data (194 from 49907; 777 from 369901). Estimated versus observed all-cause two-year mortality rates were compared. ePrognosis score was calculated based on age, sex, and daily function (derived from EORTC QLQ-C30). ePrognosis scores range from 0 to 10, with higher scores indicating worse prognosis based on mortality of community-dwelling elders and were categorized into three groups (0-2, 3-6, 7-10). Observed mortality rates were estimated using Kaplan-Meier methods. RESULTS: Patient mean age was 75.8 years (range 70-91) and 73% had stage I-IIA disease. Most patients were classified by ePrognosis as good prognosis (n = 562, 58% 0-2) and few (n = 18, 2% 7-10) poor prognosis. Two-year observed mortality rates were significantly lower than ePrognosis estimates for patients scoring 0-2 (2% vs 5%, p = 0.001) and 3-6 (8% vs 12%, p = 0.01). The same trend was seen with scores of 7-10 (23% vs 36%, p = 0.25). CONCLUSIONS: ePrognosis tool only modestly overestimates mortality rate in older breast cancer patients enrolled in two cooperative group studies. This tool, which estimates non-cancer mortality risk based on readily available clinical information may inform adjuvant therapy decisions but should be validated in non-clinical trial populations.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

June 2017

Volume

163

Issue

2

Start / End Page

391 / 398

Location

Netherlands

Related Subject Headings

  • Quality of Life
  • Prognosis
  • Oncology & Carcinogenesis
  • Leukemia
  • Kaplan-Meier Estimate
  • Humans
  • Female
  • Clinical Trials as Topic
  • Breast Neoplasms
  • Aged, 80 and over
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kimmick, G. G., Major, B., Clapp, J., Sloan, J., Pitcher, B., Ballman, K., … Mandelblatt, J. (2017). Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat, 163(2), 391–398. https://doi.org/10.1007/s10549-017-4188-6
Kimmick, Gretchen G., Brittny Major, Jonathan Clapp, Jeff Sloan, Brandelyn Pitcher, Karla Ballman, Myra Barginear, et al. “Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).Breast Cancer Res Treat 163, no. 2 (June 2017): 391–98. https://doi.org/10.1007/s10549-017-4188-6.
Kimmick GG, Major B, Clapp J, Sloan J, Pitcher B, Ballman K, et al. Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat. 2017 Jun;163(2):391–8.
Kimmick, Gretchen G., et al. “Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).Breast Cancer Res Treat, vol. 163, no. 2, June 2017, pp. 391–98. Pubmed, doi:10.1007/s10549-017-4188-6.
Kimmick GG, Major B, Clapp J, Sloan J, Pitcher B, Ballman K, Barginear M, Freedman RA, Artz A, Klepin HD, Lafky JM, Hopkins J, Winer E, Hudis C, Muss H, Cohen H, Jatoi A, Hurria A, Mandelblatt J. Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat. 2017 Jun;163(2):391–398.
Journal cover image

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

June 2017

Volume

163

Issue

2

Start / End Page

391 / 398

Location

Netherlands

Related Subject Headings

  • Quality of Life
  • Prognosis
  • Oncology & Carcinogenesis
  • Leukemia
  • Kaplan-Meier Estimate
  • Humans
  • Female
  • Clinical Trials as Topic
  • Breast Neoplasms
  • Aged, 80 and over